Gerald L. DeNardo - Concepedia

Author

Gerald L. DeNardo

Also Known As

G DeNardo, G L DENARDO, G L DeNardo, G L Denardo, G. Denardo, G. L DeNardo, G. L. DENARDO, G. L. DeNardo, G. L. Denardo, G.L DeNardo

396

Publications

9.4K

Citations

H-Index

203

Concepts

All Affiliations

University of California, Davis University of California Davis Medical Center Palmetto Hematology Oncology Lawrence Livermore National Laboratory University of California, San Francisco

About

Gerald L. DeNardo is an author at University of California, Davis specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	90	3.7K
2	Health Sciences	24	49	1.6K
3	Engineering	10	10	493
4	Natural Sciences	8	8	334
5	Public Health	4	4	249

Gerald L. DeNardo

186

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Sally J. DeNardo, Laird Miers, Kathleen R. Lamborn, PubMed Endothelial CellsImmunologyCell DeathCmrit MiceTumor Biology	2002	213
Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy Sally J. DeNardo, Gerald L. DeNardo, Laird Miers, Clinical Cancer Research	2005	197
Application of High Amplitude Alternating Magnetic Fields for Heat Induction of Nanoparticles Localized in Cancer Robert Ivkov, Sally J. DeNardo, Wolfgang Daum, Clinical Cancer Research	2005	185
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. Gerald L. DeNardo, Sally J. DeNardo, D S Goldstein, Journal of Clinical Oncology	1998	182
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. S.V. Deshpande, Sally J. DeNardo, David L. Kukis, PubMed ImmunologyBiological TherapyImmunotherapeuticsImmunotherapyTumor Uptake	1990	150
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice. Sally J. DeNardo, Gerald L. DeNardo, Arutselvan Natarajan, PubMed	2007	143
Rationales, evidence, and design considerations for fractionated radioimmunotherapy Gerald L. DeNardo, J Schlom, Donald J. Buchsbaum, Cancer	2002	126
Treatment of B cell malignancies with131I LYM-1 monoclonal antibodies Sally J. DeNardo, Gerald L. DeNardo, L.F. O'Grady, International Journal of Cancer	1988	115
Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Gerald L. DeNardo, Sally J. DeNardo, L.F. O'Grady, PubMed B-cell MalignanciesLymphoid NeoplasiaHematological MalignancyMedicineMalignant Blood Disorder	1990	114
NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics Arutselvan Natarajan, Cordula Gruettner, Robert Ivkov, Bioconjugate Chemistry NanoparticlesNanomedicineNanoferrite ParticleEngineeringNanomaterials	2008	113

Page 1